Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSC) may be
useful for the treatment of several clinical disorders, including sepsis, acute renal failure,
acute myocardial infarction, and more recently, acute lung injury (ALI). This article provides a
brief review of the biologic qualities of MSC that make them suitable for the treatment of
human diseases, as well as the experimental data that provide support for their potential
efficacy for critically ill patients with acute respiratory failure from ALI. The article then …